Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01271790 · ClinicalTrials.gov registry record · Phase 2
A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 245
- Enrollment target
NCT01271790 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 245 participants.
The verdict
NCT01271790, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 245 participants
- Enrollment target
Study Summary
This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of a 4-drug regimen with GS-9451 and Tegobuvir and 24 weeks of a 3-drug regimen of GS-9451 without Tegobuvir, all with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®).
Interventions
- DRUG GS-9451
- DRUG Tegobuvir (GS-9190)
- BIOLOGICAL Pegasys®
- DRUG Copegus®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01271790
The ClinicalTrials.gov registry entry for NCT01271790 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which GS-9451 is the first listed.
NCT01271790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01271790 about?
NCT01271790 is a clinical study titled "A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C". This phase 2b study will evaluate the efficacy and safety of 16 and 24 weeks of a 4-drug regimen with GS-9451 and Tegobuvir and 24 weeks of a 3-drug regimen of GS-9451 without Tegobuvir, all with Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®).
What is the current status of trial NCT01271790?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 245 participants. The study started on 2010-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01271790?
The interventions under investigation include: GS-9451 (DRUG), Tegobuvir (GS-9190) (DRUG), Pegasys® (BIOLOGICAL), Copegus® (DRUG).
Who is sponsoring clinical trial NCT01271790?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.